Tirzepatide beats the original weight-loss jabs, not just placebo

Injectable weight-loss drugs have moved fast: liraglutide and semaglutide, both GLP-1 receptor agonists, are already approved for long-term weight control. Tirzepatide works differently, mimicking two gut hormones at once: glucose-dependent insulinotropic peptide (GIP) as well as GLP-1. Its diabetes trials hinted at unusually strong weight reduction, but its efficacy specifically for weight loss in people with overweight or obesity had not been fully explored. This analysis set out to measure exactly that, and to weigh the safety trade-offs alongside the headline numbers.

The researchers searched the PubMed, Cochrane and Embase databases for randomised controlled trials comparing once-weekly tirzepatide against placebo or GLP-1 receptor agonists in adults with overweight or obesity, requiring a treatment duration of at least 20 weeks. Six trials met the bar, covering 6266 participants between them. The primary outcome was the mean change in weight from baseline at each of three tirzepatide doses: 5, 10 and 15 mg. Secondary outcomes included safety profiles and the proportion of people achieving weight loss of at least 5%, 10% and 15%. Study quality and the certainty of the evidence were formally assessed.

All three once-weekly doses of tirzepatide were more effective than both placebo and GLP-1 receptor agonists, in a dose-dependent pattern. More participants on tirzepatide reached the categorical weight-loss goals of 5%, 10% and 15% than in the comparison groups. The evidence was rated high certainty for achieving at least 15% weight loss, but only moderate to low certainty for the lower thresholds. Gastrointestinal side effects looked similar between the tirzepatide doses and the GLP-1 drugs, yet they were significantly more common than with placebo, which the authors note could affect tolerability for some patients.

This pooled analysis firms up what tirzepatide's diabetes trials had suggested: the dual-hormone approach outperforms not only placebo but the established single-hormone GLP-1 drugs it followed onto the market. That matters because liraglutide and semaglutide set the previous benchmark for medical weight loss. The picture is not complete, though. The authors flag lean mass reduction and tolerability as areas requiring further investigation, and the certainty of the evidence drops below the headline finding once you look at the smaller weight-loss thresholds.

If you follow the weight-loss drug story, this is a reason to think the newer dual-action drug genuinely moves more weight than the first generation of GLP-1 medicines, not just more than doing nothing. It is equally a reason to keep the trade-offs in view: gut side effects were as common as with the older drugs and clearly more common than placebo, and how much of the lost weight is lean tissue remains unanswered. This evidence covers adults with overweight or obesity, and decisions about any of these medicines sit with a prescriber.